ATE442367T1 - Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren - Google Patents
Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitorenInfo
- Publication number
- ATE442367T1 ATE442367T1 AT03778283T AT03778283T ATE442367T1 AT E442367 T1 ATE442367 T1 AT E442367T1 AT 03778283 T AT03778283 T AT 03778283T AT 03778283 T AT03778283 T AT 03778283T AT E442367 T1 ATE442367 T1 AT E442367T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- sup
- optionally substituted
- formula
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221455A GB0221455D0 (en) | 2002-09-16 | 2002-09-16 | Compounds |
GBGB0230045.7A GB0230045D0 (en) | 2002-12-23 | 2002-12-23 | Compounds |
GB0306595A GB0306595D0 (en) | 2003-03-21 | 2003-03-21 | Compounds |
GB0308017A GB0308017D0 (en) | 2003-04-07 | 2003-04-07 | Compounds |
GB0319708A GB0319708D0 (en) | 2003-08-21 | 2003-08-21 | Compounds |
GB0321074A GB0321074D0 (en) | 2003-09-09 | 2003-09-09 | Compounds |
PCT/EP2003/011814 WO2004024728A2 (en) | 2002-09-16 | 2003-09-12 | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE442367T1 true ATE442367T1 (de) | 2009-09-15 |
Family
ID=31999797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03778283T ATE442367T1 (de) | 2002-09-16 | 2003-09-12 | Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060089375A1 (de) |
EP (1) | EP1539753B1 (de) |
JP (1) | JP2006503108A (de) |
KR (1) | KR20050052501A (de) |
CN (1) | CN100387598C (de) |
AT (1) | ATE442367T1 (de) |
AU (1) | AU2010201417A1 (de) |
BR (1) | BR0314392A (de) |
CA (1) | CA2497550A1 (de) |
CY (1) | CY1109619T1 (de) |
DE (1) | DE60329193D1 (de) |
DK (1) | DK1539753T3 (de) |
ES (1) | ES2331119T3 (de) |
IL (1) | IL166898A (de) |
IS (1) | IS7709A (de) |
MA (1) | MA27475A1 (de) |
MX (1) | MXPA05002887A (de) |
NO (1) | NO20050841L (de) |
NZ (1) | NZ538515A (de) |
PL (1) | PL375993A1 (de) |
PT (1) | PT1539753E (de) |
SI (1) | SI1539753T1 (de) |
WO (1) | WO2004024728A2 (de) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
EP1608652A1 (de) * | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidinverbindungen und deren verwendung in der medizin |
AU2004233827B2 (en) * | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
CA2557004A1 (en) * | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2005090352A1 (en) * | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
GB0405933D0 (en) * | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
WO2005095328A1 (en) | 2004-04-02 | 2005-10-13 | Glaxo Group Limited | Chemical process and new crystalline form |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US7459451B2 (en) * | 2004-07-05 | 2008-12-02 | Astellas Pharma Inc. | Pyrazolopyridine derivatives |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP1940836A1 (de) * | 2005-09-29 | 2008-07-09 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridinverbindung und deren verwendung als pde4-inhibitor |
AR058109A1 (es) | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie |
CA2644069A1 (en) | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic piperazines as pde4 inhibitors |
US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
US7723330B2 (en) * | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
KR20090003349A (ko) | 2006-04-20 | 2009-01-09 | 글락소 그룹 리미티드 | 화합물 |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
TW200817006A (en) | 2006-06-23 | 2008-04-16 | Smithkline Beecham Corp | IL-8 receptor antagonist |
DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
WO2009041591A1 (ja) * | 2007-09-28 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | 縮環ピリジン誘導体 |
EP2070929A1 (de) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung |
UY31637A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
UY31636A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
CL2009000248A1 (es) * | 2008-02-06 | 2009-09-11 | Glaxo Group Ltd | Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas |
AU2009325091A1 (en) | 2008-05-23 | 2010-06-17 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein inhibitor |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
EP2408769A1 (de) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Als itk-inhibitoren verwendete pyrimidinderivate |
EA201171144A1 (ru) | 2009-03-19 | 2012-04-30 | Мерк Шарп Энд Домэ Корп. | ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2411517A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
UY32571A (es) | 2009-04-24 | 2010-11-30 | Glaxo Group Ltd | Compuestos derivados de pirazol amida |
SI2899191T1 (sl) | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji |
EP2507223A1 (de) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazolderivate als p13-kinasehemmer |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
EP2512438B1 (de) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
EP2397482A1 (de) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroarylimidazolon-Derivate als JAK-Inhibitoren |
EP2593434A1 (de) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridinverbindungen als kaliumkanalblocker |
ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
EP2614058B1 (de) | 2010-09-08 | 2015-07-08 | GlaxoSmithKline Intellectual Property Development Limited | Polymorphe und salze aus n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl]methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl]-2- (methyloxy) - 3 - pyridinyl]methansulfonamid |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
EP2630127A1 (de) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazolverbindungen, gegen allergie-, entzündungs- und immunerkrankungen |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
EP2527344A1 (de) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Als Medikamente zur Behandlung von myeloproliferativen Krankheiten, Transplantatabstossung, immunbedingten und entzündlichen Erkrankungen geeignete Pyridin-2(1H-)-on-Derivate |
US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
ES2871027T3 (es) * | 2014-03-27 | 2021-10-28 | Eicosis Llc | Inhibidores potentes de la epóxido hidrolasa soluble |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
CR20160529A (es) | 2014-05-12 | 2017-01-02 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmacéuticas para tratar enfermedades infecciosas |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
WO2016181990A1 (ja) | 2015-05-12 | 2016-11-17 | 大鵬薬品工業株式会社 | アザ二環式化合物の結晶 |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP2019524792A (ja) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
CN107964011A (zh) * | 2016-10-19 | 2018-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代吡唑并吡啶类衍生物及其医药用途 |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11512067B2 (en) | 2017-09-14 | 2022-11-29 | Daiichi Sankyo Company, Limited | Compound having cyclic structure |
US11505559B2 (en) | 2017-10-30 | 2022-11-22 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors |
US11434247B1 (en) * | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
CN116507336A (zh) | 2020-09-10 | 2023-07-28 | Vanda制药公司 | 治疗pdeiv介导的疾病或病症的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US598973A (en) * | 1898-02-15 | Water-heater and smoke-consumer | ||
US598838A (en) * | 1898-02-08 | William b | ||
US3856799A (en) * | 1971-08-05 | 1974-12-24 | Squibb & Sons Inc | Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters |
BE787249A (fr) * | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
US3833594A (en) * | 1971-08-05 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxylic acids and esters |
US3925388A (en) * | 1971-08-05 | 1975-12-09 | Squibb & Sons Inc | 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters |
US4012373A (en) * | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
US3979399A (en) * | 1972-11-15 | 1976-09-07 | E. R. Squibb & Sons, Inc. | Amino derivatives of pyrazolopyridine carboxamides |
US3840546A (en) * | 1972-11-15 | 1974-10-08 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxamides |
US3833598A (en) * | 1972-12-29 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters |
US4115394A (en) * | 1974-05-06 | 1978-09-19 | E. R. Squibb & Sons, Inc. | Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
CA2557004A1 (en) * | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
-
2003
- 2003-09-12 CN CNB038250438A patent/CN100387598C/zh not_active Expired - Fee Related
- 2003-09-12 PT PT03778283T patent/PT1539753E/pt unknown
- 2003-09-12 US US10/527,866 patent/US20060089375A1/en not_active Abandoned
- 2003-09-12 ES ES03778283T patent/ES2331119T3/es not_active Expired - Lifetime
- 2003-09-12 WO PCT/EP2003/011814 patent/WO2004024728A2/en active Application Filing
- 2003-09-12 AT AT03778283T patent/ATE442367T1/de active
- 2003-09-12 NZ NZ538515A patent/NZ538515A/en unknown
- 2003-09-12 PL PL03375993A patent/PL375993A1/xx not_active Application Discontinuation
- 2003-09-12 EP EP03778283A patent/EP1539753B1/de not_active Expired - Lifetime
- 2003-09-12 MX MXPA05002887A patent/MXPA05002887A/es active IP Right Grant
- 2003-09-12 BR BR0314392-9A patent/BR0314392A/pt not_active IP Right Cessation
- 2003-09-12 CA CA002497550A patent/CA2497550A1/en not_active Abandoned
- 2003-09-12 DE DE60329193T patent/DE60329193D1/de not_active Expired - Lifetime
- 2003-09-12 KR KR1020057004514A patent/KR20050052501A/ko not_active Application Discontinuation
- 2003-09-12 DK DK03778283T patent/DK1539753T3/da active
- 2003-09-12 SI SI200331680T patent/SI1539753T1/sl unknown
- 2003-09-12 JP JP2004571743A patent/JP2006503108A/ja active Pending
-
2005
- 2005-02-15 IL IL166898A patent/IL166898A/en not_active IP Right Cessation
- 2005-02-16 NO NO20050841A patent/NO20050841L/no unknown
- 2005-02-24 IS IS7709A patent/IS7709A/is unknown
- 2005-04-15 MA MA28224A patent/MA27475A1/fr unknown
-
2008
- 2008-01-14 US US12/013,529 patent/US20080175914A1/en not_active Abandoned
-
2009
- 2009-11-24 CY CY20091101212T patent/CY1109619T1/el unknown
-
2010
- 2010-04-08 AU AU2010201417A patent/AU2010201417A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20050841L (no) | 2005-06-15 |
CY1109619T1 (el) | 2014-08-13 |
JP2006503108A (ja) | 2006-01-26 |
PL375993A1 (en) | 2005-12-12 |
BR0314392A (pt) | 2005-07-12 |
WO2004024728A3 (en) | 2004-10-21 |
EP1539753B1 (de) | 2009-09-09 |
NZ538515A (en) | 2007-04-27 |
PT1539753E (pt) | 2009-12-10 |
CN100387598C (zh) | 2008-05-14 |
DK1539753T3 (da) | 2010-01-04 |
EP1539753A2 (de) | 2005-06-15 |
MXPA05002887A (es) | 2005-05-27 |
KR20050052501A (ko) | 2005-06-02 |
SI1539753T1 (sl) | 2009-12-31 |
DE60329193D1 (de) | 2009-10-22 |
WO2004024728A2 (en) | 2004-03-25 |
ES2331119T3 (es) | 2009-12-22 |
CN1694882A (zh) | 2005-11-09 |
US20060089375A1 (en) | 2006-04-27 |
IL166898A (en) | 2010-06-30 |
MA27475A1 (fr) | 2005-08-01 |
US20080175914A1 (en) | 2008-07-24 |
AU2010201417A1 (en) | 2010-04-29 |
AU2003285300A1 (en) | 2004-04-30 |
CA2497550A1 (en) | 2004-03-25 |
IS7709A (is) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442367T1 (de) | Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren | |
TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
NO20063340L (no) | Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer | |
GEP20104973B (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
JP2007529486A5 (de) | ||
SG179437A1 (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
CA2564201A1 (en) | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | |
ATE370138T1 (de) | Neue imidazopyridine und ihre verwendung | |
JP2013530179A (ja) | 呼吸器合胞体ウイルス(rsv)感染の処置に使用するためのウレイド−ピラゾール誘導体 | |
SG159380A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
WO2007039781A3 (en) | 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors | |
WO2006011024A3 (en) | New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | |
HK1127603A1 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | |
ID27509A (id) | Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya | |
RU2012131280A (ru) | [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез | |
RU2011134382A (ru) | Пиримидопиридазиновые производные, пригодные в качестве р38 марк | |
DE60203106D1 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
MY135776A (en) | PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
NO20082051L (no) | Arylsubstituert, nitrogeninneholdende, heterofyklisk forbindelse | |
PE20070237A1 (es) | Derivados de pirido[3',2':4,5]furo[3,2-d]pirimidina como inhibidores de pde4 | |
TH77766B (th) | สารประกอบไพราโซโล [3,4-b]ไพริดีน, และการใช้พวกมันเสมือนเป็นตัวยับยั้งฟอสโฟไดเอสเทอเรส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1539753 Country of ref document: EP |